Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAPi-PET imaging of fibrosis in inflammatory bowel disease
2022-002751-19Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of 68Ga FAPI-46 in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Baseline detection of increased 68Ga-FAPI uptake in Crohn's disease. Started Mar 2023; status: active.
02
Drugs
68Ga FAPI-46
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2022-002751-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002751-19.